Neogen Chemicals Q2 FY27 Results: Profit Up, Expands Organo-Lithium Facility
Neogen Chemicals reported Q2 FY27 profit of ₹21.14 crore, up from ₹9.31 crore YoY. Revenue from operations was ₹288.00 crore. The company approved a ₹45 crore expansion of its Organo-Lithium facility to 600 MT/PA. Material related party transactions with subsidiaries were also approved, requiring shareholder consent.
The financial results show improved profitability, and the capacity expansion is a significant strategic move that will impact future revenue and market position. The approval of material related party transactions and NCD redemption also represent substantial corporate actions.
The company reported increased profits and is undertaking a significant capacity expansion, indicating positive business growth.
Neogen Chemicals Limited announced the outcome of its Board Meeting held on October 31, 2026. The board approved the un-audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company reported a profit of ₹21.14 crore for the quarter, an increase from ₹9.31 crore in the same period last year. Revenue from operations for the quarter stood at ₹288.00 crore.
The company also approved an expansion of its Organo-Lithium chemicals manufacturing facility at Patancheru, Telangana. The capacity will be increased from 300 MT/PA to 600 MT/PA of active material, with an estimated investment of up to ₹45 crore funded by internal accruals or debt. This expansion is expected to add a revenue potential of ₹150 crore to ₹200 crore and is targeted for completion by the end of the next financial year.
Furthermore, the Board approved material related party transactions (RPTs) with its step-down subsidiary, Neogen Morita New Materials Limited (NML), and its wholly-owned subsidiary, Neogen Ionics Limited (NIL). These transactions, including corporate guarantees and loans, are proposed to be entered into between December 8, 2026, and December 7, 2027, subject to shareholder approval.
Additionally, Neogen Chemicals announced the pre-mature voluntary early redemption of 20,000 secured, listed, rated, redeemable, non-cumulative, non-convertible debentures (NCDs) aggregating ₹200 crore, issued on August 12, 2025. The company also approved a postal ballot notice for seeking shareholder approval for the aforementioned RPTs.
What to do with a filing like this
Neogen Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neogen Chemicals Limited. Read the original for the full detail.